HONG KONG, May 4, 2015 /PRNewswire/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Company", together with its subsidiaries collectively as the "Group", 801.HK; 910801.TW), a leading integrated healthcare enterprise in China announced today that it has entered into an agreement (the "Agreement") to purchase the outstanding 7% senior convertible notes due 2017 (the "Notes") issued by China Cord Blood Corporation ("CO"), a non-wholly owned subsidiary of the Group.
The Notes were originally issued by CO to KKR China Healthcare Investment Limited ("KKR") in April 2012 with an aggregate principal amount of US$65 million. The purchase consideration for the Notes is currently estimated to be approximately US$159.9 million (HK$1.2 billion) plus interest accrued on the Notes from 27 April 2015 to the date when the purchase of the Notes is completed. The purchase consideration is subject to (i) applicable distributions on the ordinary shares made by CO, if any, and (ii) any possible changes to the currently offered per ordinary share purchase price at US$6.40 as reflected in the Company's previously announced proposed "going-private" transaction, in each case, in accordance with the terms of the Agreement.
The completion of the purchase of the Notes is subject to certain closing conditions, including the approval of Golden Meditech's shareholders with respect to such purchase of the Notes.
For more information about the purchase proposal, please refer to the announcement published by the Company on 4 May 2015 under the link below:
http://www.irasia.com/listco/hk/goldenmeditech/announcement/a141106-egm.pdf
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited (www.goldenmeditech.com) is China's leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices, and cord blood storage and hospital management businesses of thehealthcare services markets, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
